Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis

References

• Ando Y, Coelho T, Berk JL, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013;8:31.
   PubMed Web of Science ®Google Scholar
• Coelho T, Ericzon BG, Falk R, et al. A guide to transthyretin amyloidosis. Clarkston, MI: Amyloidosis Foundation; 2016 cited 2019 Mar 27. http://www.amyloidosis.org/wp-content/uploads/2017/05/2017-ATTR-guide.pdf
   Google Scholar
• Galant NJ, Westermark P, Higaki JN, et al. Transthyretin amyloidosis: an under-recognized neuropathy and cardiomyopathy. Clin Sci (Lond). 2017;131(5):395−409.
   PubMed Web of Science ®Google Scholar
• Obici L. Becoming familiar with hereditary transthyretin amyloidosis, a treatable neuropathy. Arq Neuropsiquiatr. 2018;76(9):573–574.
   PubMed Web of Science ®Google Scholar
• Gertz MA. Hereditary attr amyloidosis: burden of illness and diagnostic challenges. Am J Manag Care. 2017;23(7 Suppl):S107–s112.
   PubMed Web of Science ®Google Scholar
• Conceicao I, Gonzalez-Duarte A, Obici L, et al. “Red-flag” symptom clusters in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Syst. 2016;21(1):5–9.
   PubMed Web of Science ®Google Scholar
• Donnelly JP, Hanna M. Cardiac amyloidosis: an update on diagnosis and treatment. Cleve Clin J Med. 2017;84(12 Suppl 3):12–26.
   PubMed Web of Science ®Google Scholar
• Hawkins PN, Ando Y, Dispenzeri A, et al. Evolving landscape in the management of transthyretin amyloidosis. Ann Med. 2015;47(8):625–638.
   PubMed Web of Science ®Google Scholar
• Adams D, Coelho T, Obici L, et al. Rapid progression of familial amyloidotic polyneuropathy: a multinational natural history study. Neurology. 2015;85(8):675–682.
   PubMed Web of Science ®Google Scholar
• Hanna M. Novel drugs targeting transthyretin amyloidosis. Curr Heart Fail Rep. 2014;11(1):50–57.
   PubMedGoogle Scholar
• Schmidt HH, Waddington-Cruz M, Botteman MF, et al. Estimating the global prevalence of transthyretin familial amyloid polyneuropathy. Muscle Nerve. 2018;57(5):829–837.
   PubMed Web of Science ®Google Scholar
• Liz MA, Mar FM, Franquinho F, et al. Aboard transthyretin: from transport to cleavage. IUBMB Life. 2010;62(6):429–435.
   PubMed Web of Science ®Google Scholar
• Rowczenio DM, Noor I, Gillmore JD, et al. Online registry for mutations in hereditary amyloidosis including nomenclature recommendations. Hum Mutat. 2014;35(9):E2403–E2412.
   PubMed Web of Science ®Google Scholar
• Coelho T, Maurer MS, Suhr OB. Thaos - the transthyretin amyloidosis outcomes survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Curr Med Res Opin. 2013;29(1):63–76.
   PubMed Web of Science ®Google Scholar
• Center for Drug Evaluation and Research. Onpattro 2 mg/mL injection for intravenous use. [cited 2019 Mar 27]. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210922Orig1s000Approv.pdf
   Google Scholar
• European Medicines Agency. Onpattro (patisiran): an overview of Onpattro and why it is authorised in the EU. [cited 2019 Mar 27]. https://www.ema.europa.eu/documents/overview/onpattro-epar-medicine-overview_en.pdf
   Google Scholar
• Center for Drug Evaluation and Research. Tegsedi injection, 189 mg/mL. [cited 2019 Mar 27]. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211172Orig1s000Approv.pdf
   Google Scholar
• European Medicines Agency. Tegsedi (inotersen): an overview of Tegsedi and why it is authorised in the EU. [cited 2019 Mar 27]. https://www.ema.europa.eu/documents/overview/tegsedi-epar-summary-public_en.pdf
   Google Scholar
• Holmgren G, Ericzon BG, Groth CG, et al. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet. 1993;341(8853):1113–1116.
   PubMed Web of Science ®Google Scholar
• Adams D, Samuel D, Goulon-Goeau C, et al. The course and prognostic factors of familial amyloid polyneuropathy after liver transplantation. Brain. 2000;123(Pt 7):1495–1504.
   PubMed Web of Science ®Google Scholar
• Maia LF, Magalhaes R, Freitas J, et al. CNS involvement in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings. J Neurol Neurosurg Psychiatry. 2015;86(2):159–167.
   PubMed Web of Science ®Google Scholar
• Davis MK, Kale P, Liedtke M, et al. Outcomes after heart transplantation for amyloid cardiomyopathy in the modern era. Am J Transplant. 2015;15(3):650–658.
   PubMed Web of Science ®Google Scholar
• Berk JL, Suhr OB, Obici L, et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA. 2013;310(24):2658–2667.
   PubMed Web of Science ®Google Scholar
• Said G, Grippon S, Kirkpatrick P. Tafamidis. Nat Rev Drug Discov. 2012;11(3):185–186.
   PubMed Web of Science ®Google Scholar
• Vyndaqel [summary of product characteristics]. Bruxelles, Belgium: Pfizer Europe MA EEIG; 2018.
   Google Scholar
• Kristen AV, Ajroud-Driss S, Conceicao I, et al. Patisiran, an rnai therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis. Neurodegener Dis Manag. 2019;9(1):5–23.
   PubMed Web of Science ®Google Scholar
• Coelho T, Maia LF, Da SA M, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012;79(8):785–792.
   PubMed Web of Science ®Google Scholar
• Barroso FA, Judge DP, Ebede B, et al. Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years. Amyloid. 2017;24(3):194–204.
   PubMed Web of Science ®Google Scholar
• Keohane D, Schwartz J, Gundapaneni B, et al. Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial. Amyloid. 2017;24(1):30–36.
   PubMed Web of Science ®Google Scholar
• Mundayat R, Stewart M, Alvir J, et al. Positive effectiveness of tafamidis in delaying disease progression in transthyretin familial amyloid polyneuropathy up to 2 years: an analysis from the transthyretin amyloidosis outcomes survey (THAOS). Neurol Ther. 2018;7(1):87–101.
   PubMed Web of Science ®Google Scholar
• Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007–1016.
   PubMed Web of Science ®Google Scholar
• Vyndaqel [prescribing information]. New York, NY: Pfizer Labs; 2019 May.
   Google Scholar
• Adams D, Gonzalez-Duarte A, O’Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11–21.
   PubMed Web of Science ®Google Scholar
• Verona G, Mangione PP, Raimondi S, et al. Inhibition of the mechano-enzymatic amyloidogenesis of transthyretin: role of ligand affinity, binding cooperativity and occupancy of the inner channel. Sci Rep. 2017;7(1):182.
   PubMedGoogle Scholar
• Sant’Anna R, Gallego P, Robinson LZ, et al. Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity. Nat Commun. 2016;7:10787.
   PubMed Web of Science ®Google Scholar
• Kolstoe SE, Mangione PP, Bellotti V, et al. Trapping of palindromic ligands within native transthyretin prevents amyloid formation. Proc Natl Acad Sci U S A. 2010;107(47):20483–20488.
   PubMed Web of Science ®Google Scholar
• Mu Y, Jin S, Shen J, et al. CHF5074 (CSP-1103) stabilizes human transthyretin in mice humanized at the transthyretin and retinol-binding protein loci. FEBS Lett. 2015;589(7):849–856.
   PubMed Web of Science ®Google Scholar
• Qiang L, Guan Y, Li X, et al. CSP-1103 (CHF5074) stabilizes human transthyretin in healthy human subjects. Amyloid. 2017;24(1):42–51.
   PubMed Web of Science ®Google Scholar
• Miller M, Pal A, Albusairi W, et al. Enthalpy-driven stabilization of transthyretin by AG10 mimics a naturally occurring genetic variant that protects from transthyretin amyloidosis. J Med Chem. 2018;61(17):7862–7876.
   PubMed Web of Science ®Google Scholar
• Penchala SC, Connelly S, Wang Y, et al. AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin. Proc Natl Acad Sci U S A. 2013;110(24):9992–9997.
   PubMed Web of Science ®Google Scholar
• Cardoso I, Martins D, Ribeiro T, et al. Synergy of combined doxycycline/TUDCA treatment in lowering transthyretin deposition and associated biomarkers: studies in FAP mouse models. J Transl Med. 2010;8:74.
   PubMed Web of Science ®Google Scholar
• Obici L, Cortese A, Lozza A, et al. Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study. Amyloid. 2012;19(Suppl 1):34–36.
   PubMed Web of Science ®Google Scholar
• Richards DB, Cookson LM, Berges AC, et al. Therapeutic clearance of amyloid by antibodies to serum amyloid P component. N Engl J Med. 2015;373(12):1106–1114.
   PubMed Web of Science ®Google Scholar
• Higaki JN, Chakrabartty A, Galant NJ, et al. Novel conformation-specific monoclonal antibodies against amyloidogenic forms of transthyretin. Amyloid. 2016;23(2):86–97.
   PubMed Web of Science ®Google Scholar
• Galant NJ, Bugyei-Twum A, Rakhit R, et al. Substoichiometric inhibition of transthyretin misfolding by immune-targeting sparsely populated misfolding intermediates: a potential diagnostic and therapeutic for TTR amyloidoses. Sci Rep. 2016;6:25080.
   PubMed Web of Science ®Google Scholar
• Benson MD, Dasgupta NR, Monia BP. Inotersen (transthyretin-specific antisense oligonucleotide) for treatment of transthyretin amyloidosis. Neurodegener Dis Manag. 2019;9(1):25–30.
   PubMed Web of Science ®Google Scholar
• Tegsedi [prescribing information]. Boston, MA: Akcea Therapeutics;October2018
   Google Scholar
• Niemietz CJ, Sauer V, Stella J, et al. Evaluation of therapeutic oligonucleotides for familial amyloid polyneuropathy in patient-derived hepatocyte-like cells. PLoS One. 2016;11(9):e0161455.
   PubMed Web of Science ®Google Scholar
• Ackermann EJ, Guo S, Benson MD, et al. Suppressing transthyretin production in mice, monkeys and humans using 2nd-generation antisense oligonucleotides. Amyloid. 2016;23(3):148–157.
   PubMed Web of Science ®Google Scholar
• Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):22–31.
   PubMed Web of Science ®Google Scholar
• Tegsedi [summary of product characteristics]. London, UK: Akcea Therapeutics UK Ltd.; 2018.
   Google Scholar
• Waddington-Cruz M, Ackermann EJ, Polydefkis M, et al. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO-TTR trial. Amyloid. 2018;25(3):180–188.
   PubMed Web of Science ®Google Scholar
• Brannagan T, Wang AK, Coelho T, et al. Long-term update from the open-label extension of the NEURO-TTR study in patients with hereditary transthyretin amyloidosis. Presented at: American Society of Hematology Annual Meeting and Exposition; December 1–4, 2018; San Diego, CA.
   Google Scholar
• Benson MD, Dasgupta NR, Rissing SM, et al. Safety and efficacy of a TTR specific antisense oligonucleotide in patients with transthyretin amyloid cardiomyopathy. Amyloid. 2017;24(4):219–225.
   PubMed Web of Science ®Google Scholar
• Benson MD, Teague SD, Kovacs R, et al. Rate of progression of transthyretin amyloidosis. Am J Cardiol. 2011;108(2):285–289.
   PubMed Web of Science ®Google Scholar
• Schmidt HH, Barroso F, Gonzalez-Duarte A, et al. Management of asymptomatic gene carriers of transthyretin familial amyloid polyneuropathy. Muscle Nerve. 2016;54(3):353–360.
   PubMed Web of Science ®Google Scholar
• Obici L, Kuks JB, Buades J, et al. Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis. Curr Opin Neurol. 2016;29(Suppl 1):S27–35.
   PubMedGoogle Scholar
• Ericzon BG, Wilczek HE, Larsson M, et al. Liver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative? Transplantation. 2015;99(9):1847–1854.
   PubMed Web of Science ®Google Scholar
• Rosenblum H, Castano A, Alvarez J, et al. (transthyretin) stabilizers are associated with improved survival in patients with TTR cardiac amyloidosis. Circ Heart Fail. 2018;11(4):e004769.
   PubMed Web of Science ®Google Scholar
• Beirao JM, Malheiro J, Lemos C, et al. Ophthalmological manifestations in hereditary transthyretin (ATTR V30M) carriers: a review of 513 cases. Amyloid. 2015;22(2):117–122.
   PubMed Web of Science ®Google Scholar